Revolution Medicines, Inc. (RVMD)
$193.95+2.21%Close
SELLRECOVERY · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $41.2B
- Beta
- 1.41
- P/E (TTM)
- -22.56
- Short % float
- 6.27%
- Days to cover
- 4.7
- SI change
- +23.3%
- 1W
- -6.61%
- 1M
- -4.82%
- vs SPY 1W
- -7.03%
- vs SPY 1M
- -6.88%
Industry peers
FMP comparable companies · ranked by market cap
- ERASSELLErasca, Inc.$5.4BRECOVERYQ 4$15.46-3.56%
- RLAYSELLRelay Therapeutics, Inc.$3.8BRECOVERYQ 3$17.41+0.56%
- TNGXSELLTango Therapeutics, Inc.$3.7BRECOVERYQ 24$22.57+1.51%
- IDYASELLIDEAYA Biosciences, Inc.$3.4BBEARQ 25$36.06-0.14%
- ELVNSELLEnliven Therapeutics, Inc.$2.9BCRISISQ 11$40.63-0.34%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.21-0.85%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$12.03-1.50%
- GLUESELLMonte Rosa Therapeutics, Inc.$872MCRISISQ 8$10.32+2.14%
- VSTMBUYVerastem, Inc.$713MRECOVERYQ 4$8.11-1.55%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on RVMD?
- LOPJLB’s latest quantitative signal on Revolution Medicines, Inc. (RVMD) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is RVMD in?
- Revolution Medicines, Inc. (RVMD) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Revolution Medicines, Inc. (RVMD) do?
- Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and color…